Poliomyelitis vaccination Infections and Infestations Poliomyelitis
Conditions
Interventions
Patients will be randomised between:
1. A fractional dose of IPV (0.1 ml or 1/5 of a dose) administered intradermally by needle-free device - potency of IPV is 40-8-32-D antigen units
Sponsors
World Health Organization (WHO) (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy newborns (greater than 2.5 kg, apgar score greater than 9 at five minutes) 2. Living within the catchment area of the participating polyclinics 3. Newborns delivered by caesarian section
Exclusion criteria
Exclusion criteria: 1. Newborns requiring hospitalisation (except if in hospital because of maternal admission) 2. Birth weight below 2.5 kg 3. Apgar score less than 9 4. Residence outside the catchment area, or families expecting to move away during the study period 5. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family) will also render the newborn ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion by neutralisation assay between birth and 18 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Seroconversion by neutralisation assay after each dose of study vaccines. | — |
Countries
Cuba, Switzerland
Outcome results
None listed